Creative Peptides posted this:L-Ornithine α-Ketoglutarate MonohydrateL-Ornithine is a non-essential amino acid, metabolized to generate L-arginine, which is further incorporated into proteins. α-Ketoglutarate is a key intermediate in the Krebs cycle, coming after isocitrate and before succinyl CoA. Acting as a co-substrate, α-Ketoglutarate also plays important function in oxidation reactions involving molecular oxygen.http://www.creative-peptides.com/product/l-ornithine-ketoglutarate-monohydrate-item-10-101-118-72.html
Creative Peptides posted this:Lysipressin lysine vasopressin; LVP; Lysipressin; LysopressinLysipressin is a pressor peptide isolated from marsupials and pigs that binds to VP receptors, which are analogous to human Vasopressin 2 (V2) receptors. Lysipressin induces contractions in smooth muscle and potentiates effects of gastric lesioning in animal models.http://www.creative-peptides.com/product/lysipressin-item-10-101-23-73.html
Creative Peptides posted this:MOG (35-55) MOG(35-55); MOG35-55; MOG 35-55; Myelin Oligodendrocyte Glycoprotein(35-55)Myelin Oligodendrocyte Glycoprotein (MOG) is a glycoprotein believed to be important in the process of myelinization of nerves in the central nervous system (CNS). It is a transmembrane protein expressed on the surface of oligodendrocyte cell and on the outermost surface of myelin sheaths.http://www.creative-peptides.com/product/mog-item-10-101-57-74.html
Creative Peptides posted this:Montirelin CG 3703; CG-3703; CG3703; CNK 602A; CNK602AMontirelin stimulates the release of thyrotropin and prolactin. It is synthesized by the neurons in the paraventricular nucleus of the hypothalamus. After being released into the pituitary portal circulation, TRH (was called TRF) stimulates the release of TSH and PRL from the anterior pituitary gland.http://www.creative-peptides.com/product/montirelin-item-10-101-64-75.html
Creative Peptides posted this:APIs Octreotide acetate cas 83150-76-9Octreotide acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. It inhibits the secretion of gastro-entero-pancreatic peptide hormones and the release of growth hormone. We provide Octreotide Acetate. More information please visit the website:http://www.creative-peptides.com/product/octreotide-acetate-item-10-101-26-80.html
Technology Transfer Office
RAMOT at Tel Aviv University Ltd. posted this:A novel approach for a genome-wide detection of synthetically-lethal genes in cancer: Towards rational drug target identification and personalized treatmentsSynthetic lethality occurs when a perturbation of two nonessential genes is lethal. This phenomenon offers a unique opportunity to develop selective anticancer drugs that will target a gene whose Synthetic Lethal (SL)-partner is inactive only in the cancer cells. Towards the realization of this potential, screening technologies have been developed to detect SL-interactions in model organisms and in human cell lines. However, currently their scope falls short compared to the large spectrum of interactions that need to be surveyed in cancer. Here we present a data-driven computational pipeline for the genome-wide identification of SL-interactions in cancer, by analyzing large volumes of genomic profiles of cancer cell lines and clinical samples. Our approach is first shown to successfully capture the SL-partners of tumor suppressors and oncogenes, according to six published experimental SL-screens. Second, we construct the first genome-wide network of SL-interactions in cancer and demonstrate its utility in predicting gene essentiality in a cancer-specific manner. Third, we show that, as predicted, underexpression of SL-partners has a strong positive prognostic value for cancer survival. Fourth, we identify synthetic lethality arising from gene over-activation and show that it can be utilized to predict anticancer drug efficacy. Lastly, we develop a complementary computational approach that by harnessing the obtained SL-networks identifies the most suitable treatment per patient, and identifies novel anticancer drug-targets, providing drug repurposing leads. Our approach provides a solid basis guiding future experimental studies aimed at developing new, selective anticancer therapies. Project ID : 2-2013-713
Universidad de Alcalá-OTRI posted this:Portable device to detect, diagnose and monitoring of tyrosinemiaA Spanish research Group from Analytical Chemistry, Physical Chemistry and Chemical Engineering Departments at University of Alcala (Spain) has designed and developed a metabolic rare disease sensor to diagnose and monitoring tyrosinemia in different biological fluidics (blood, plasma and urine) using very few amounts of the sample without any pretreatment. This device uses a non-invasive approach for and in situ monitoring of the disease, even by the own patient at home. The group is looking for companies to manufacturing a prototype, reaching licensing agreements or collaboration.
Universidad de Alcalá-OTRI posted this:Universal sensor platform for immunoassayThe research group in Bioelectrochemistry and Biosensors of the University of Alcalá has developed a method for the construction of a universal analytical device that allows the adaptation of any ELISA format to an immunosensor format, in order to develop simple, low cost and easy to use sensors. This device is based on the sequential deposition of self-assembled monolayers of polymers and affinity elements, applicable for the detection and quantification of any analyte or target antigen in a liquid sample, which allows the development of "on-demand" immunosensors. The group looks for companies or institutions from agro-food, bio-sanitary and environmental sector, interested in reaching collaboration agreements, commercial agreements with technical assistance or patent licensing.
Universidad de Alcalá-OTRI posted this:Nanoconjugates formed by dendritic molecules and peptides as antitumor agents against advanced prostate cancer.The Research Group in "Dendrimers for Biomedical Applications" of the University of Alcalá presents a new invention that refers to the formation of nanoconjugates with antitumor activity, mainly against advanced prostate cancer. Nanoconjugates are composed of dendritic systems (dendrimers and dendrons) and neuropeptides. The dendritic molecules are mainly of carbosilane structure and with ammonium functions in the periphery. And the peptides are preferably of the glucagon / secretin family (VIP, GHRH, PACAP…etc.) The research group seeks companies from the Biomedicine, Pharmaceutical and Health sector, to establish licensing agreements, cooperation agreements or commercial agreements with technical assistance.